Sign in

You're signed outSign in or to get full access.

Alex Blumenfrucht

Director at RELI
Board

About Alex Blumenfrucht

Alex Blumenfrucht (age 37) has served on Reliance Global Group’s Board since 2018; he previously served as RELI’s Chief Financial Officer from 2018 until June 1, 2022 and is currently CFO of Future Care Consultants, following Audit & Assurance experience at Deloitte & Touche (2015–2018) . The Board cites his internal control, financial analysis, and public company reporting expertise as central to RELI’s finance and controls .

Past Roles

OrganizationRoleTenureCommittees/Impact
Reliance Global Group, Inc.Chief Financial Officer2018 – June 1, 2022CFO overseeing financial vision, cash flow, budgeting, financial planning
Deloitte & Touche LLPAudit & Assurance Professional (Audit Senior)Sept 2015 – May 2018Led audits of public and private companies

External Roles

OrganizationRoleTenureNotes
Future Care ConsultantsChief Financial Officer2022 – PresentUnaffiliated company serving nursing homes

Board Governance

  • Committee assignments: Not listed on key Board committees. Audit, Compensation, and Nominating & Corporate Governance Committees are comprised of independent directors Scott Korman, Ben Fruchtzweig, and Sheldon Brickman; chairs are Korman (Audit), Fruchtzweig (Compensation), Brickman (Nominating & Governance) .
  • Attendance and engagement: Board held 14 meetings in FY2024; each incumbent director attended at least 75% of Board and applicable committee meetings. All directors virtually attended the 2024 Annual Meeting; all expected for 2025 Annual Meeting .
  • Independence designation: The proxy identifies committee members as independent; Alex is not included on committees. The filing does not explicitly state his independence status for Board purposes .
  • 2025 shareholder vote support: Re-elected with 1,090,972 votes “For,” 15,851 “Abstain,” broker non-votes 710,958 .

Fixed Compensation (Director)

Metric (FY2024)Amount
Annual cash fees$45,000
Stock awards (grant-date fair value)$11,766
OptionsNone disclosed
Total$56,766

Performance Compensation

  • Non-employee director equity cap: Under the 2025 Equity Incentive Plan, non-employee directors may not receive awards with grant-date fair value exceeding $300,000 in any fiscal year .
  • Plan features: Options/SARs must be granted at or above fair market value; awards may include performance-based vesting .
  • Performance metric framework (available for awards under the plan; not specifically tied to Alex’s 2024 director award): | Metric Category | Examples | |---|---| | Profitability | Net income, operating income, EPS | | Growth/Revenue | Gross revenue, net revenue, sales | | Returns | ROE, ROA, return on capital | | Cash/Capital | Cash flow, free cash flow, debt to capital | | Market-based | Stock price, total shareholder return | | Operational | Overhead reductions, recruiting/retention |

Other Directorships & Interlocks

  • No public company directorships disclosed for Alex; current external role is CFO at Future Care Consultants (private) .

Expertise & Qualifications

  • Internal control, financial analysis, and public company reporting expertise recognized by the Board .
  • Audit pedigree from Deloitte & Touche (public and private company audits) .

Equity Ownership

HolderShares Beneficially Owned% of Shares Outstanding
Alex Blumenfrucht36,7331.23%
Shares Outstanding (Record Date 3/31/2025)2,974,869
  • Anti-hedging/anti-pledging: Company policy prohibits hedging or pledging of company stock for all employees and directors .

Governance Assessment

  • Strengths
    • Financial controls and reporting expertise; prior CFO tenure and audit background enhance Board effectiveness in oversight of finance and controls .
    • Meaningful ownership (1.23%), aligning interests with shareholders; anti-hedge/pledge policy supports alignment .
    • Engagement: At least 75% attendance standard met by incumbents; shareholder support in 2025 director election indicates investor confidence .
  • Watch items / Red flags
    • Committee independence: He is not on Audit, Compensation, or Nominating & Governance committees (each composed of independent directors), limiting his role in key oversight forums; independence status for Board purposes not explicitly disclosed .
    • Former executive overlap: Served as RELI CFO until June 1, 2022; continued Board service may raise independence considerations even as the filing does not expressly designate director independence by individual .
    • Section 16 compliance: One late Form 4 filing in FY2024 noted for Alex (each director mentioned had one late filing), a minor compliance lapse to monitor .

Related-Party Exposure

  • Family relationships: None disclosed for Alex; only Ezra and Yaakov Beyman are father/son among officers/directors .
  • Transactions: No related-party transactions involving Alex disclosed in the proxy; anti-hedging/pledging policy in place .

Say-on-Pay & Shareholder Feedback (context)

  • 2025 Say-on-Pay passed: For 1,082,884; Against 21,626; Abstain 2,313; broker non-votes 710,958, indicating strong support for compensation framework .

Compensation Structure Notes (context)

  • Equity plans: The company expanded long-term incentive design via the 2024 Omnibus Plan (1,000,000 shares reserved) and proposed 2025 Equity Plan (2,000,000 shares), with performance features and non-employee director caps; repricing restrictions require shareholder approval under plan rules .

Risk Indicators

  • Legal proceedings: No director or executive (including Alex) involved in legal/regulatory proceedings under Item 401(f) in the past 10 years .
  • Anti-hedging/pledging policy reduces alignment risks .
  • Late Section 16 filings: Alex noted for one late Form 4 in FY2024 .